Results 11 to 20 of about 12,911,083 (257)

Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas^® HBV Test for Use on the Cobas^® 4800 System

Microorganisms, 2021
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection.
Valérie Ortonne, Mélanie Wlassow, Magali Bouvier-Alias, Giovana Melica, Jean-Dominique Poveda, Syria Laperche, Jean-Michel Pawlotsky, Stephane Chevaliez   +7 more
doaj   +1 more source

Boosting Diverse Communities Participation in Clinical Trials: What People Living with Hepatitis B Must Know [PDF]

BioSocial Health Journal
Introduction: Globally, people from African, Asian and Western Pacific regions are disproportionately affected by hepatitis B virus (HBV) and are underrepresented in HBV clinical trials (trials).
Yasmin Ibrahim, Tanya Machado, Fiona Borondy-Jenkins, Shreya Koirala, Mi Dong, Ibrahima Sankare, Mohamed Ali, Dung Hua, Ashley Che, Chari Cohen   +9 more
doaj   +1 more source

IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection

Viruses, 2022
The Na+/taurocholate co-transporting polypeptide (NTCP, gene symbol SLC10A1) is both a physiological bile acid transporter and the high-affinity hepatic receptor for the hepatitis B and D viruses (HBV/HDV).
Massimo Palatini, Simon Franz Müller, Michael Kirstgen, Silke Leiting, Felix Lehmann, Lena Soppa, Nora Goldmann, Christin Müller, Kira Alessandra Alicia Theresa Lowjaga, Jörg Alber, Giuliano Ciarimboli, John Ziebuhr, Dieter Glebe, Joachim Geyer   +13 more
doaj   +1 more source

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors

Viruses, 2021
Identification of Na+/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV
Michael Kirstgen, Kira Alessandra Alicia Theresa Lowjaga, Simon Franz Müller, Nora Goldmann, Felix Lehmann, Dieter Glebe, Karl-Heinz Baringhaus, Joachim Geyer   +7 more
doaj   +1 more source

Barriers to accessing hepatitis B medication: a qualitative study from the USA and Canada

BMJ Open
Objectives To collect and document the numerous barriers that people living with hepatitis B (PLHB) encounter when trying to access their hepatitis B virus (HBV) medications.Design Researchers collected qualitative data through 24 online interviews.
Sophie Jacob, Michaela Jackson, Yasmin Ibrahim, Catherine Freeland, Beatrice Zovich, Chari Cohen   +5 more
doaj   +1 more source

Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac

Vaccines, 2021
Background and aims: Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn.
Rifaat Safadi, Tawfik Khoury, Nizar Saed, Marwan Hakim, Jeryes Jamalia, Yousef Nijim, Nicola Farah, Tawfik Nuser, Nidaa Natur, Mahmud Mahamid, Johnny Amer, Pia L. Roppert, Wolfram H. Gerlich, Dieter Glebe   +13 more
doaj   +1 more source

Hepatitis B : are you at risk? [PDF]

Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop an \u201cacute\u201d infection, which can range in severity from a very mild illness with few or no symptoms to a ...

core   +4 more sources

Best practices for engaging with affected communities: chronic hepatitis B as a case study

Infectious Diseases of Poverty
Hepatitis B is the single most common cause of liver cancer, affecting > 250 million people worldwide (mostly in resource limited communities) and killing > 1 million people annually. The condition is marked by poor rates of diagnosis (14%) and treatment
Thomas Tu, Nafisa Yussf, Lien Tran, Kim Ngo, Su Wang, Adi Mondel, Isabelle Purcell, Jacki Chen, Wendy Lo, Bright Ansah, Kenneth Kabagambe, Soumen Basu, Dee Lee, Supa Chantschool, Chris Munoz, Ivana Dragojevic, Marko Korenjak, Fiona Borondy-Jenkins, Yasmin Ibrahim, Beatrice Zovich, Chari Cohen   +20 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA

Harm Reduction Journal
Background People who use drugs (PWUD) are at increased risk for blood-borne viruses, including hepatitis B (HBV) and delta (HDV). Despite the public health threats both viruses present, awareness remains low among at-risk communities and providers who ...
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Amy Jessop, Rachel Holbert, Fiona Borondy-Jenkins, Quinn Plunkett, Chari Cohen   +9 more
doaj   +1 more source